目的 探討曲美布汀聯(lián)合奧替溴銨治療腸易激綜合征的臨床效果。方法 選取2016年8月-2017年8月在通城縣人民醫(yī)院治療的腸易激綜合征患者76例，隨機分為對照組（36例）和治療組（40例）。對照組口服奧替溴銨片，80 mg/次，2次/d。治療組在對照組基礎(chǔ)上餐前30 min口服馬來酸曲美布汀片，200 mg/次，3次/d。兩組患者均持續(xù)治療4周。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀改善時間及P物質(zhì)（SP）、生長抑素（SS）和神經(jīng)肽Y（NPY）水平。結(jié)果 治療后，對照組和治療組的臨床總有效率分別為77.78%、95.00%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，治療組腹部不適、大便性狀與次數(shù)改善的時間均顯著短于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者SP、SS水平較治療前顯著下降，NPY水平顯著升高，同組比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組SP、SS和NPY水平顯著優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 曲美布汀聯(lián)合奧替溴銨治療腸易激綜合征療效顯著，安全性好，具有一定的臨床推廣應(yīng)用價值。

Objective To discuss the clinical effect of trimebutine combined otilonium bromide in treatment of irritable bowel syndrome. Methods Patients (76 cases) with irritable bowel syndrome in Tongcheng Hospital from August 2016 to August 2017 were randomly divided into control (36 cases) and treatment (40 cases) groups. Patients in the control group were po administered with Otilonium Bromide Tablets, 80 mg/time, twice daily. Patients in the treatment group were po administered with Trimebutine Maleate Tablets on the basis of the control group 30 min before the meal, 200 mg/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the improvement time of clinical symptom, as well as SP, SS and NPY levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 77.78% and 95.00%, respectively, and there were differences between two groups (P < 0.05). After treatment, the improvement time of abdominal discomfort, stool characters and times in the treatment group was significantly shorter than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the SP and SS levels in two groups were significantly decreased, but NPY level was significantly increased, and there were differences in the same group (P < 0.05). And the SP, SS and NPY levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Trimebutine combined otilonium bromide has significant curative effect in treatment of irritable bowel syndrome with high safety, which has a certain clinical application value.